Uniunea Europeană - română - EMA (European Medicines Agency)

celgene europe bv - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Uniunea Europeană - română - EMA (European Medicines Agency)

celgene europe ltd. - lepirudina - thromboembolism; thrombocytopenia - agenți antitrombotici - anticoagulare la pacienţii adulţi cu trombocitopenie indusă de heparină de tip ii şi boală tromboembolică mandatarea parenterale terapia antitrombotica. diagnosticul trebuie confirmat prin indusă de heparină de activare plachetară test sau un test echivalent.

Uniunea Europeană - română - EMA (European Medicines Agency)

celgene europe ltd. - romidepsin - limfom, non-hodgkin - agenți antineoplazici - tratamentul periferic cu celule t limfom (ptcl),.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - thalidomide - mielom multiplu - imunosupresoare - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

celgene europe limited - marea britanie - paclitaxelum - pulb. pt. susp. perf. - 5mg/ml - alcaloizi din plante si alte produse naturale taxani

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - mielom multiplu - imunosupresoare - imnovid în asociere cu bortezomib și dexametazonă este indicat în tratamentul pacienților adulți cu mielom multiplu care au primit anterior cel puțin un tratament inclusiv lenalidomidă. imnovid în combinaţie cu dexametazona este indicat în tratamentul pacienţilor adulţi cu mielom multiplu recidivat si refractar, care au primit cel puţin două regimuri de tratament anterior, inclusiv atât lenalidomidă şi bortezomib, şi au demonstrat progresia bolii pe ultima terapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenți antineoplazici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenți antineoplazici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

celgene distribution b.v. - olanda - paclitaxelum - pulb. pt. dispersie perf. - 5mg/ml - alcaloizi din plante si alte produse naturale taxani